Wedbush Predicts Reduced Earnings for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for Travere Therapeutics in a research report issued on Monday, February 24th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.43) per share for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics' Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.56) EPS.

A number of other research analysts have also recently commented on the company. Piper Sandler increased their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. increased their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research note on Wednesday. Citigroup increased their price target on Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Scotiabank increased their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Travere Therapeutics in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.62.

Remove Ads

Travere Therapeutics Price Performance

Shares of TVTX traded up $0.76 during trading hours on Thursday, reaching $21.40. The stock had a trading volume of 2,003,508 shares, compared to its average volume of 1,656,869. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $25.29. The stock has a market capitalization of $1.90 billion, a PE ratio of -5.22 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The company's 50-day moving average is $20.05 and its two-hundred day moving average is $17.06.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million.

Institutional Trading of Travere Therapeutics

Several large investors have recently made changes to their positions in TVTX. Creative Planning grew its stake in shares of Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company's stock valued at $335,000 after buying an additional 995 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Travere Therapeutics by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company's stock valued at $206,000 after buying an additional 5,767 shares during the period. Rice Hall James & Associates LLC grew its stake in shares of Travere Therapeutics by 24.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company's stock valued at $1,325,000 after buying an additional 18,562 shares during the period. Emerald Mutual Fund Advisers Trust grew its stake in shares of Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company's stock valued at $16,588,000 after buying an additional 244,444 shares during the period. Finally, Emerald Advisers LLC lifted its position in Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company's stock valued at $27,430,000 after acquiring an additional 323,513 shares in the last quarter.

Insiders Place Their Bets

In other Travere Therapeutics news, CFO Christopher R. Cline sold 5,192 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the completion of the sale, the chief financial officer now directly owns 90,038 shares in the company, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now owns 83,170 shares of the company's stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,335 shares of company stock worth $4,453,012. Company insiders own 3.75% of the company's stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.